Lördag 2 Augusti | 10:37:10 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-08-29 12:20 Kvartalsrapport 2025-Q2
2025-07-03 - Extra Bolagsstämma 2025
2025-05-30 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2025-03-18 - Bokslutskommuniké 2024
2025-01-14 - Split OBSRV 15:1
2024-08-26 - Kvartalsrapport 2024-Q2
2024-05-27 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2024-05-24 - Årsstämma
2024-03-13 - Bokslutskommuniké 2023
2023-11-22 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-11-03 - 15-10 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2022-06-03 - Årsstämma
2022-03-29 - Bokslutskommuniké 2021
2022-02-04 - Extra Bolagsstämma 2022
2021-11-03 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-25 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 - Årsstämma
2020-06-16 - Extra Bolagsstämma 2020
2020-05-12 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamt inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2025-07-22 16:16:23

Oslo, 22 July 2025

Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted in total 2,600,000 share options to primary insider and CEO of the Company, Jørgen Mann, and primary insider and CFO of the Company, Johan Fagerli.

Each share option gives the right to purchase one share in the Company. Shares acquired through exercise of options will be subject to a lock-up period of 12 months, subject to customary exceptions. The share options will vest over a period of two years. 1/3 of the share options vested today on the award date, 1/3 of the share options will vest on the first anniversary of the award date, and 1/3 of the share options will vest on the second anniversary of the award date. The share options will be exercisable during specific exercise periods from their vesting date and until 22 July 2028 and will lapse if not exercised within this date.

In total 700,000 of the granted share options, of which 500,000 options have been granted to Jørgen Mann and 200,000 options have been granted to Johan Fagerli, may be exercised at an exercise price of NOK 2.00 per share. The remaining 1,900,000 share options, of which 1,500,000 option have been granted to Jørgen Mann and 400,000 options have been granted to Johan Fagerli, may be exercised at an exercise price of NOK 0.50 per share. Following the grants, Jørgen Mann holds 840,000 shares and 3,000,000 options in the Company, while Johan Fagerli holds 356,716 shares and 1,100,000 options in the Company.

For more information about the grant of share options to the primary insiders, see the attached forms regarding mandatory notifications of trade.

This information is subject to disclosure requirements pursuant to Article 19 of Regulation EU 596/2014 (the EU Market Abuse Regulation) and Section 5 -12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical: 

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialisation of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.